Endophenotyping Oxaliplatin Hypersensitivity: Personalizing Desensitization to the Atypical Platin

Area of Science:

• Oncology
• Clinical Immunology
• Pharmacology

Background:

• Oxaliplatin induces diverse immediate hypersensitivity reactions, unlike other platinum-based chemotherapeutics.
• Reactions vary from Type 1 (responsive to desensitization) to atypical cytokine release syndromes (refractory to desensitization).
• Personalized, evidence-based strategies are crucial for managing oxaliplatin-hypersensitive patients.

Purpose of the Study:

• To develop a data-driven algorithm for optimizing treatment in oxaliplatin-hypersensitive patients.
• To personalize desensitization protocols based on individual patient reaction endophenotypes.

Main Methods:

• Retrospective analysis of 48 oxaliplatin-hypersensitive patients undergoing 266 desensitizations.
• Characterization of four endophenotypes: Type 1, cytokine release, mixed, and either.
• Utilized clinical characteristics, biomarkers (e.g., IL-6), and desensitization outcomes.

Main Results:

• Identified four distinct endophenotypes of oxaliplatin hypersensitivity.
• Elevated IL-6 levels (40-fold increase) characterized the cytokine release endophenotype.
• Younger patients were more prone to cytokine release, older patients to Type 1 reactions.
• Skin testing was not predictive of endophenotype or desensitization outcomes.
• Atopic patients with Type 1 reactions responded well to antihistamines; nonatopic patients often shifted to cytokine release/mixed reactions.

Conclusions:

• Endophenotyping oxaliplatin hypersensitivity reactions aids in predicting desensitization outcomes.
• Personalized treatment plans can be developed based on identified endophenotypes.
• This strategy optimizes therapeutic management for hypersensitive patients.